Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;54(3):1117-24.
doi: 10.1128/AAC.01114-09. Epub 2009 Dec 22.

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models

Affiliations

Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models

Rajesh V Dudhani et al. Antimicrob Agents Chemother. 2010 Mar.

Abstract

Colistin is increasingly used as last-line therapy against Gram-negative pathogens. The pharmacokinetic (PK)/pharmacodynamic (PD) index that best correlates with the efficacy of colistin remains undefined. The activity of colistin against three strains of Pseudomonas aeruginosa was studied in neutropenic mouse thigh and lung infection models. The PKs of unbound colistin were determined from single-dose PK studies together with extensive plasma protein binding analyses. Dose-fractionation studies were conducted over 24 h with a dose range of 5 to 160 mg/kg of body weight/day. The bacterial burden in the thigh or lung was measured at 24 h after the initiation of treatment. Relationships between antibacterial effect and measures of exposure to unbound (f) colistin (area under the concentration-time curve [fAUC/MIC], maximum concentration of drug in plasma [fC(max)]/MIC, and the time that the concentration in plasma is greater than the MIC [fT > MIC]) were examined by using an inhibitory sigmoid maximum-effect model. Nonlinearity in the PKs of colistin, including its plasma protein binding, was observed. The PK/PD index that correlated best with its efficacy was fAUC/MIC in both the thigh infection model (R(2) = 87%) and the lung infection model (R(2) = 89%). The fAUC/MIC targets required to achieve 1-log and 2-log kill against the three strains were 15.6 to 22.8 and 27.6 to 36.1, respectively, in the thigh infection model, while the corresponding values were 12.2 to 16.7 and 36.9 to 45.9 in the lung infection model. The findings of this in vivo study indicate the importance of achieving adequate time-averaged exposure to colistin. The results will facilitate efforts to define the more rational design of dosage regimens for humans.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
fu of colistin against the end-dialysis plasma concentration of colistin in the equilibrium dialysis study. The solid line is a four-parameter model fit obtained by nonlinear least-squares regression (R2 = 98%) of the experimental data: fu = −3.45 + 3.91/(1 + exp{− [x −(−21.41)]}/10.09), where x is the plasma colistin concentration.
FIG. 2.
FIG. 2.
Total (A) and unbound (B) plasma colistin concentrations versus time after administration of single subcutaneous doses of 5, 10, 20, or 40 mg/kg colistin (sulfate) in neutropenic infected mice. (C and D) Corresponding data on semilogarithmic coordinates. Each symbol represents the mean ± standard deviation for four mice.
FIG. 3.
FIG. 3.
Relationships for P. aeruginosa ATCC 27853 between the log10 CFU per thigh at 24 h and the PK/PD indices fAUC/MIC (A), fCmax/MIC (B), and fT > MIC (C). Each symbol represents the datum from a single thigh. The dotted lines represent the mean bacterial burden in the thighs at the start of treatment.
FIG. 4.
FIG. 4.
Relationships for P. aeruginosa strain ATCC 27853 between the log10 CFU per lung at 24 h and the PK/PD indices fAUC/MIC (A), fCmax/MIC (B), and fT > MIC (C). Each symbol represents the datum from a single lung. The dotted lines represent the mean bacterial burden in the lungs at the start of treatment.

Similar articles

Cited by

References

    1. Bergen, P. J., J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642. - PubMed
    1. Bergen, P. J., J. Li, C. R. Rayner, and R. L. Nation. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. - PMC - PubMed
    1. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. - PubMed
    1. Bradley, J. S., R. Guidos, S. Baragona, J. G. Bartlett, E. Rubinstein, G. G. Zhanel, M. D. Tino, D. L. Pompliano, F. Tally, and P. Tipirneni. 2007. Anti-infective research and development—problems, challenges, and solutions. Lancet Infect. Dis. 7:68-78. - PubMed
    1. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement (M100-S17). Clinical and Laboratory Standards Institute, Wayne, PA.

Publication types

MeSH terms